Revenue grew 11% year-over-year to $114.4 million in Q2 2026, driven by a 32% increase in exome and genome test volumes, but higher operating expenses and a $31.3 million impairment charge led to a net loss of $17.7 million. Adjusted net income was $0.4 million, and the company ended the quarter wi…
Revenue grew 11% year-over-year to $114.4 million in Q2 2026, driven by a 32% increase in exome and genome test volumes, but higher operating expenses and a $31.3 million impairment charge led to a net loss of $17.7 million. Adjusted net income was $0.4 million, and the company ended the quarter with $132.5 million in cash and securities.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
